Tilray Imports Bulk Supply of Medical Cannabis Oil Into The United Kingdom

CANADA: Tilray, a global pioneer in cannabis research, cultivation, production and distribution, today announced it has imported medical cannabis oral solutions in bulk into the United Kingdom from its Good Manufacturing Practices (GMP)-certified facility in Canada. This export allows Tilray to provide authorized U.K. patients in need with a locally maintained supply of medical cannabis oral solutions.
 
In September 2018, Tilray announced the successful import of Tilray 2:100 medical cannabis oil for a pediatric patient in need in the United Kingdom. Tilray’s 2:100 cannabis oil was supplied via a government-approved special access program following the U.K. Home Secretary’s historic announcement that declared prescriptions of cannabis-derived medicines legal for patients with an exceptional clinical need.
 
“As demand ramps up in the U.K., Tilray is well positioned to be a leading supplier of medical cannabis products,” says Sascha Mielcarek, Managing Director of Tilray Europe. “Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients’ quality of life. We’re pleased to reaffirm our commitment to delivering medical cannabis to patients in the U.K. and look forward to offering a variety of GMP-certified, pharmaceutical-grade products in the coming months.”
 
Tilray has six medical cannabis products approved for medical use in the U.K. that can be made available to patients with medical cannabis prescriptions obtained through private practice or the National Health Service. Tilray anticipates supplying a variety of cannabidiol (CBD)-dominant, tetrahydrocannabinol (THC)-dominant and balanced oral solutions for patients looking to use medicines derived from cannabis.
 
“This bulk import of Tilray medical cannabis oral solutions provides patients in need access to a sustained supply of GMP-certified, high quality medical cannabis,” says Catherine Jacobson, Tilray’s Vice President of Medical and Regulatory Affairs. “This is an important step in improving access in the U.K. Tilray will continue to advocate for reasonable patient access to medical cannabis in the U.K. and countries around the world.”

Study: Cannabis Inhalation Not Associated With COPD, Other Tobacco-Related Harms

UNITED KINGDOM: Cannabis smoke exposure, even long-term, is not positively associated with chronic obstructive pulmonary disease (COPD), lung cancer, or irreversible airway damage, according to a literature review published in the journal Breathe.

Study: CBD Effective As Adjunctive Therapy For Schizophrenia

UNITED KINGDOM: The daily administration of CBD (cannabidiol) as an adjunctive therapy mitigates psychotic symptoms in patients with schizophrenia, according to clinical trial data published online ahead of print in The American Journal of Psychiatry.

British researchers assessed the adjunctive use of CBD compared to placebo over a six-week period in a randomized trial of 88 schizophrenic patients. Participants ingested 1000mg of plant-derived CBD per day in addition to their conventional medications.

Subjects in the CBD treatment group “had lower levels of positive psychotic symptoms and were more likely to have been rated as improved and as not severely unwell by the treating clinician” at the conclusion of the trial. CBD administration was also associated with “improvements in cognitive performance and in the level of overall functioning,” although these changes did not reach statistical significance.

“These findings suggest that CBD has beneficial effects in patients with schizophrenia,” authors concluded. “As CBD’s effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.”

Results of a prior clinical trial published in the journal Translational Psychiatry determined that CBD is superior to amisulpride, a potent anti-psychotic agent, in mitigating psychotic symptoms in schizophrenic patients.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial,” appears in The American Journal of Psychiatry.

Study: CBD Administration Reduces Blood Pressure

UNITED KINGDOM: Oral CBD administration is associated with reduced blood pressure in healthy volunteers, according to clinical trial data published online in the Journal of Clinical Investigation.

Investigators from the University of Nottingham assessed the effects of a single oral dose of 600 mg of CBD extract versus placebo in nine male subjects.

Cannabidiol administration reduced resting systolic blood pressure and stroke volume (the amount of blood pumped by the left ventricle of the heart in one contraction). Compared to placebo, CBD intake was associated with reduced BP levels following exercise and in response to stress. Increased heart rate was observed following CBD administration, but no “adverse events” were reported by participants either during or following the study sessions.

Authors concluded: “Our data show that a single dose of CBD reduces resting blood pressure and the blood pressure response to stress, particularly cold stress, and especially in the post-test periods. This may reflect the anxiolytic and analgesic effects of CBD, as well as any potential direct cardiovascular effects. … Further research is also required to establish whether CBD has any role in the treatment of cardiovascular disorders such as a hypertension.”

 

Clinical Trial: THCV Lowers Blood Sugar Levels In Type 2 Diabetics

UNITED KINGDOM: The administration of THCV (tetrahydrocannabivarin), a non-psychoactive component of cannabis, is positively associated with glycemic control in type 2 diabetics, according to the randomized, placebo-controlled data published in the journal Diabetes Care.

Investigators from the University of Nottingham, School of Medicine assessed the twice daily administration of various cannabinoids (CBD or THCV or CBD and THCV in combination) versus placebo over a period of 13 weeks in 62 non-insulin dependent subjects with type 2 diabetes.

Authors reported that the administration of THCV alone “significantly decreased fasting plasma glucose” levels and improved pancreatic cell function. By contrast, other treatment therapies failed to show detectable metabolic effects.

Investigators concluded, “THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.”

Population-based observational studies have previously reported that cannabis consumers typically possess lower BMI and other favorable indices related to diabetic control compared to those without a history of marijuana use.

Twins Study Finds No Evidence That Marijuana Lowers IQ In Teens

UNITED KINGDOM: Roughly half of Americans use marijuana at some point in their lives, and many start as teenagers. Although some studies suggest the drug could harm the maturing adolescent brain, the true risk is controversial. Now, in the first study of its kind, scientists have analyzed long-term marijuana use in teens, comparing IQ changes in twin siblings who either used or abstained from marijuana for 10 years. After taking environmental factors into account, the scientists found no measurable link between marijuana use and lower IQ.

“This is a very well-conducted study … and a welcome addition to the literature,” says Valerie Curran, a psychopharmacologist at the University College London. She and her colleagues reached “broadly the same conclusions” in a separate, non-twin study of more than2000 British teenagers, published earlier this month in the Journal of Psychopharmacology, she says. But, warning that the study has important limitations, George Patton, a psychiatric epidemiologist at the University of Melbourne in Australia, adds that it in no way proves that marijuana—particularly heavy, or chronic use —is safe for teenagers.

Most studies that linked marijuana to cognitive deficits, such as memory loss and low IQ, looked at a single “snapshot” in time, says statistician Nicholas Jackson of the University of Southern California in Los Angeles, lead author of the new work. That makes it impossible to tell which came first: drug use or poor cognitive performance. “It’s a classic chicken-egg scenario,” he says.

 

Study: High-Potency Marijuana Linked With Neural Damage

GREAT BRITAIN:  In scanning the brains of drug users, researchers at Kings College London found smokers of high-potency pot had smaller amounts of white brain matter inside their corpus callosum, a neural pathway connecting the left and right halves of the brain.

While pot smokers generally showed more damage to the corpus callosum than non-smokers, those who smoked super strong weed known as ‘skunk’ showed more significant white matter loss.

Scientists performed MRI scans on the brains of 56 patients who had visited a London hospital reporting a first episode of psychosis. The brains of 43 healthy participants were also scanned. All the participants were surveyed about their drug habits.

MPs Set To Debate Legalizing Cannabis On October 12

UNITED KINGDOM:  MPs are set to debate whether the UK should legalize the production, sale and possession of cannabis after a petition calling for drug law reform attracted more than 200,000 signatures. The government confirmed a debate led by Labour MP Paul Flynn will take place in Westminster Hall on 12 October. Flynn, MP for Newport West, has campaigned for the cannabis reform for 25 years and is also a long-time advocate of medical marijuana.

The debate is in response to a popular parliamentary petition that argued legalizing cannabis could bring in “£900m ($1.3 Billion) in taxes every year, save £400m ($614 Million) on policing cannabis and create over 10,000 new jobs”. The petition took just four days to amass 125,000 signatures after it was launched in July.

However, it is unlikely the debate will have any effect on the current drugs laws. In response to the petition, a government spokesperson said: “Substantial scientific evidence shows cannabis is a harmful drug that can damage human health. There are no plans to legalize cannabis as it would not address the harm to individuals and communities.”

First Legal ‘Charlotte’s Web’ Cannabis Oil To Go On Sale In The UK

GREAT BRITAIN:  Cannabis oil has become increasingly sought after as an alternative treatment for a range of conditions including severe epilepsy, but legislators have been unwilling to legalise it due to its association with marijuana.

Thanks to the work of advocates including CNN’s Dr Sanjay Gupta – who famously reversed his stance on medical marijuana to become a staunch supporter – and documentaries such as The Culture High, the wider public and legislators have come to see CBD oil’s medical value.

UK CBD are the first British company to sell ‘Charlotte’s Web’ cannabis oil since it was made legal on 31 July. Charlotte’s Web products are derived from low THC – the major psychoactive component in marijuana – high CBD – which is not psychoactive – cannabis strains. In other words they do not induce the ‘high’ associated with recreational marijuana. These varieties of cannabis are commonly referred to as hemp.

 

Marijuana Legalization 2015: United Kingdom Could Legalize Weed After 150,000 Brits Sign Petition

GREAT BRITAIN: United Kingdom lawmakers may consider a bill that would legalize cannabis after an online petition garnered the support of more than 150,000 people. The petition asks for lawmakers to allow the sale, production and use of marijuana.

Petitions that exceed more than 100,000 signatures require a formal response from the government and the House of Commons must consider putting the item to debate. Those which receive the required number of signatures are “almost always debated,” according to the site. The petition, which was introduced last week, has amassed more than 158,000 signatures.

The creator of the petition, James Richard Owen, argues that the U.K. is wasting money by keeping marijuana criminalized. “Legalizing cannabis could bring in £900m in taxes every year, save £400m on policing cannabis and create over 10,000 new jobs,” Owen wrote. He said marijuana is a “substance that is safer than alcohol, and has many uses. It is believed to have been used by humans for over 4000 years, being made illegal in the U.K. in 1925.”